Document Detail


The dynamic nature of the kinome.
MedLine Citation:
PMID:  23343193     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recent advances in proteomics have facilitated the analysis of the kinome 'en masse'. What these studies have revealed is a surprisingly dynamic network of kinase responses to highly selective kinase inhibitors, thereby illustrating the complex biological responses to these small molecules. Moreover these studies have identified key transcription factors, such as c-Myc and FOXO (forkhead box O), that play pivotal roles in kinome reprogramming in cancer cells. Since many kinase inhibitors fail despite a high efficacy of blocking their intended targets, elucidating kinome changes at a more global level will be essential to understanding the mechanisms of kinase inhibitor pharmacology. The development of technologies to study the kinome, as well as examples of kinome resilience and reprogramming, will be discussed in the present review.
Authors:
Lee M Graves; James S Duncan; Martin C Whittle; Gary L Johnson
Related Documents :
23082153 - Nf1 rasgap inhibition of limk2 mediates a new cross-talk between ras and rho pathways.
16595703 - Induction of steroidogenesis in immature rat leydig cells by interleukin-1alpha is depe...
12517973 - Cpg dna induces self and cross-hyporesponsiveness of raw264.7 cells in response to cpg ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  The Biochemical journal     Volume:  450     ISSN:  1470-8728     ISO Abbreviation:  Biochem. J.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-24     Completed Date:  2013-03-28     Revised Date:  2013-12-16    
Medline Journal Info:
Nlm Unique ID:  2984726R     Medline TA:  Biochem J     Country:  England    
Other Details:
Languages:  eng     Pagination:  1-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents / pharmacology,  therapeutic use
Drug Resistance, Neoplasm
Humans
Protein Kinase Inhibitors / pharmacology,  therapeutic use
Protein Kinases / chemistry,  metabolism*
Proteomics
Grant Support
ID/Acronym/Agency:
DK037871/DK/NIDDK NIH HHS; R01 GM101141/GM/NIGMS NIH HHS; T32 CA071341/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Protein Kinase Inhibitors; EC 2.7.-/Protein Kinases
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Development of a solid-phase receptor-based assay for the detection of cyclic imines using a microsp...
Next Document:  Wnt/?-catenin signalling: from plasma membrane to nucleus.